SynthesisClinical rheumatology2025
Kikuchi-Fujimoto in the light of the COVID-19: infection and vaccination. A systematic review.
Synthesis in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between SARS-CoV-2 infection, COVID-19 vaccination, and the development of autoimmune diseases such as the Kikuchi-Fujimoto disease (KFD) is currently unknown.
aimsThis study aims to review, synthesize, and analyze the current available evidence on the occurrence of KFD associated with both SARS-CoV-2 infection and COVID-19 vaccination.
methodsCase report, case series, and observational studies were included. Narrative review studies, systematic reviews, meta-analyses, etc., were excluded. A selective bibliographic search was performed in the following databases: PubMed, Scopus, EMBASE, and Web of Science until January 26, 2025. The Joanna Briggs Institute (JBI) tool was used to assess the risk of bias and quality of the studies. The SPSS Statistics tool (version 25.0; IBM Corp., Armonk, N. Y., USA) was used for statistical analysis.
resultsA total of 52 patients were reported in the included studies. Of these, 16 developed new-onset KFD as a complication of SARS-CoV-2 infection, while 36 presented with the disease as an adverse effect of COVID-19 vaccination. Cases associated with infection had a mean age of 27.25 ± 16.87 years, and the most frequent clinical manifestations were fever, fatigue, cough, and weight loss. On the other hand, cases related to vaccination had a mean age of 30.8 ± 12.63 years, with a greater association to mRNA technology vaccines, particularly Pfizer-BioNTech (75%) and Moderna (11.1%). Most cases were related to the administration of the first dose (75%). There was a predominance of female sex and the presence of cervical lymphadenopathy in both groups. There were no cases of mortality or unfavorable evolution; on the contrary, almost all patients evolved favorably after timely diagnosis and adequate treatment.
conclusionsSARS-CoV-2 infection could represent a new causative agent of KF disease. However, its occurrence as an adverse effect of COVID-19 vaccination is rare and infrequent, which may be attributed to limited case reporting and the relative novelty of the disease. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024522470.
Indexed as
Identifiers
40610704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.